Drug intelligence / Profile preview

CT11a1-ADC

Development stage: Preclinical
Lead developer: Nordic Bioscience
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CT11a1-ADC is an antibody-drug conjugate (ADC) developed by Nordic Bioscience that targets a tumor-specific epitope of type XI collagen. Type XI collagen is a marker of myofibroblastic cancer-associated fibroblasts (myCAFs), which contribute to the dense stromal barrier and increased tissue stiffness in fibrotic tumors like pancreatic cancer. By utilizing the CT11a1 antibody as a delivery vehicle for a cytotoxic payload, this therapeutic candidate aims to selectively eliminate myCAFs within the tumor microenvironment, potentially facilitating drug delivery and overcoming therapeutic resistance. The program is complemented by the PRO-C11 circulating biomarker for patient selection and monitoring.

Targets

COL11A1

Beyond the preview

Go deeper on CT11a1-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT11a1-ADC.

Explore the full profile